Ciprofloxacin Pharmacokinetics/Pharmacodynamics against Susceptible and Low-Level Resistant Escherichia coli Isolates in an Experimental Ascending Urinary Tract Infection Model in Mice
Lotte Jakobsen, Carina Vingsbo Lundberg, Niels Frimodt‐Møller
Abstract
The mouse ascending urinary tract infection model was used to study the pharmacokinetic/pharmacodynamic (PKPD) relationships of the effect of ciprofloxacin in subcutaneous treatment for 3 days with varying doses and dosing intervals against a susceptible Escherichia coli strain (MIC, 0.032 mg/liter). Further, a humanized dose of ciprofloxacin was administered for 3 days against three E. coli strains with low-level resistance, i.e., MICs of 0.06, 0.25, and 1 mg/liter, respectively.
Topics & Concepts
CiprofloxacinPharmacokineticsPharmacodynamicsEscherichia coliDosingPharmacologyLiterUrinary systemMicrobiologyMedicineAntibioticsBiologyInternal medicineBiochemistryGeneAntibiotics Pharmacokinetics and EfficacyAntibiotic Resistance in BacteriaDrug Transport and Resistance Mechanisms